Oasmia Pharmaceutical AB   Report issue

For profit Phase 3
Founded: Uppsala Sweden (1990)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2009
NCT00989131
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Ovarian Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1